Buscar ubicaciones
Para conocer los horarios, visitas sin turno y citas.Synonyms
- BioFire
- FilmArray
Test Includes
Adenovirus; Bordetella pertussis; Bordetella parapetussis: Chlamydophila pneumoniae; SARS-CoV-2; coronavirus 229E; coronavirus HKU1; coronavirus NL63; coronavirus OC43; human metapneumovirus; human rhinovirus/enterovirus; influenza A; influenza A subtype H1; influenza A subtype H3; influenza A subtype H1-2009; influenza B; Mycoplasma pneumoniae; parainfluenza virus 1; parainfluenza virus 2; parainfluenza virus 3; parainfluenza virus 4; respiratory syncytial virus
Expected Turnaround Time
2 - 4 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
|
|
|
2 - 4 days |
Related Information
Related Documents
Specimen Requirements
Specimen
Nasopharyngeal swab
Volume
One swab in viral or universal transport (VTM/UTM) medium
Minimum Volume
One swab in 0.3 mL transport medium
Container
Viral transport medium
Collection
Collect NP swab per standard techniques and immediately place swab in up to 3 mL of viral transport media.
Storage Instructions
Freeze. Per the package insert: Swabs in viral transport media are stable for 30 days at -15°C or below. Swabs in viral transport media are also stable for 4 hours at room temperature and 3 days refrigerated (2º to 8ºC).
Causes for Rejection
Improper collection; inadequate specimen; improper labeling; specimen leaked in transit; quantity not sufficient for analysis; name discrepancies; specimen exceeding storage requirements; nasal swabs or any other upper respiratory sample other than nasopharyngeal swab in viral transport media
Test Details
Use
This test provides simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs obtained from individuals suspected of respiratory tract infections.
Note: Labcorp also offers smaller targeted panels for Influenza, RSV and SARS-CoV-2 (see test numbers 140140, 140147 or 140163).
Limitations
The performance of this test has not been established for patients without signs and symptoms of respiratory infection. Results from this test must be correlated with the clinical history, epidemiological data, and other data available to the clinician evaluating the patient. Viral and bacterial nucleic acids may persist in vivo independent of organism viability. Detection of organism target(s) does not imply that the corresponding organisms are infectious or are the causative agents for clinical symptoms. The detection of viral and bacterial nucleic acid is dependent upon proper specimen collection, handling, transportation, storage and preparation. Failure to observe proper procedures in any one of these steps can lead to incorrect results. There is a risk of false positive or false negative values resulting from improperly collected, transported or handled specimens.
Methodology
Polymerase chain reaction (PCR)
LOINC® Map
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf